TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03961984

Intervention type: PROCEDURE
Intervention: Biodesign® anal fistula plug
Description: Patient in general anesthesia and lithotomy position. Mucosa excision of the internal fistula opening is performed. The plug was prepared in 0.9% sodium chloride, and secured to the endoluminal brush by a suture with a 2-0 vicryl tie. The narrow end of the of the plug was then pulled through the internal opening into the fistula tract. The plug was pulled until it covered the whole length of the fistula and blocked the internal opening, the excess plug material coming out through the external opening. The plug was fixed at the internal opening by reabsorbable 3-0 sutures. Special attention was paid to ensuring that the plug was covered by mucosa when closing the internal opening. The excess plug material was trimmed by the external opening that was left open for drainage.
Study: NCT03391063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polyamide
Description: metal reinforced polyamide denture base material

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: heat cured acrylic resin
Description: conventional heat cured acrylic resin denture base material
Study: NCT01977664

Intervention type: OTHER
Intervention: no intervention
Study: NCT01973673

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bone health educational materials
Study: NCT00496782

Intervention type: DRUG
Group type: OTHER
Intervention: maraviroc
Description: Treatment-experienced subjects on failed therapy, with HIV RNA ≥ 1000 copies/mL, are eligible who will receive a tropism assay at screening (Day -14 to 0). Subjects who are eligible will receive maraviroc added to a failing regimen from Day 1 to 14. On day 15, subjects will discontinue the current treatment regimen and begin a new OBT. Subjects with only R5 HIV will continue receiving maraviroc plus OBT. Subjects with non-R5 virus will discontinue receiving maraviroc but continue to receive the new OBT. Investigator selects OBT based on results of phenotype/genotype testing at baseline. The nominal dose for maraviroc is 300 mg BID. The maraviroc dose should be adjusted based on OBT patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Trofile Assay and HIV RNA quantification assay
Description: Trofile Assay and HIV RNA quantification assay
Study: NCT03303352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS FNA
Description: Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will be randomly allocated to receive EUS FNA (endoscopic ultrasound fine needle aspiration).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS FNA
Description: Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will be randomly allocated to receive EUS FNA (endoscopic ultrasound fine needle aspiration).
Study: NCT02221882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3164530
Description: Administered IV.
Study: NCT01870765

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-invasive ventilation
Description: non-invasive ventilation via face mask
Study: NCT02273219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Description: Oral, 100-400 mg twice daily A potent, oral, selective inhibitor of the classical Protein Kinase C (PKC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: Oral, 200-350 mg daily An oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: Oral, 200-350 mg daily An oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: Oral, 200-350 mg daily An oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: Oral, 200-350 mg daily An oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: Oral, 200-350 mg daily An oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds
Study: NCT04124107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multiparametric MRI and 68Ga-PSMA PET/MRI
Description: All participants will undergo multiparametric MRI examination. If mpMRI is unfavorable for prostate cancer, participants will undergo 68Ga-PSMA PET/MRI examination

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostate biopsy
Description: Participants with unfavorable mpMRI but favorable 68Ga-PSMA PET/MRI will undergo both 68Ga-PSMA PET/MRI-ultrasound-fusion targeted biopsy and transperineal ultrasound guided 12-core systematic biopsy
Study: NCT03639766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA
Description: AbobotulinumtoxinA reconstituted in non-bacteriostatic saline solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Non-bacteriostatic saline solution
Study: NCT03808168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Protocol dose: 3mg/kg mg as a 30-minute IV infusion on Day 1 (Arm I) or Days 1, 15, 29 (Arm II).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Protocol dose: 3mg/kg mg as a 30-minute IV infusion on Day 1 (Arm I) or Days 1, 15, 29 (Arm II).
Study: NCT04099784

Intervention type: OTHER
Intervention: Physical development and General Health
Description: Physical development and General health examination

Intervention type: OTHER
Intervention: Physical development and General Health
Description: Physical development and General health examination

Intervention type: OTHER
Intervention: Developmental Red flags
Description: Developmental Red flags Questionnaires
Study: NCT00005833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R115777
Description: 300mg P.O. BID.
Study: NCT02321462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eziclen
Description: Eziclen solution administered orally as split-dose the day before and on the day of colonoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fortrans®
Description: Fortrans® solution administered orally as split-dose the day before and on the day of colonoscopy.
Study: NCT02196324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: serlopitant
Description: NK1 receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02382081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient-initiated shared care
Study: NCT01615471

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group weight loss with companion internet
Description: Monthly in-person group sessions with an companion internet weight loss intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group weight loss with companion internet
Description: Monthly in-person group sessions with an companion internet weight loss intervention
Study: NCT01677091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical vibration
Description: Vibration of neck muscles during 10 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical vibration
Description: Vibration of neck muscles during 10 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prism adaptation
Description: Prism adaptation during 10 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prism adaptation
Description: Prism adaptation during 10 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: conventional rehabilitation
Study: NCT02635191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tailored Group
Description: All the patients who enrolled in this arm will be received endoscopy followed by biopsy for antimicrobial susceptibility testing and cytochrome P450 isoenzyme 2C19 genotype. 10 days tailored therapy will be given including one Proton Pump Inhibitor ( Rabeprazole0.4-0.5mg/kg.d,bid. or Esomeprazole0.8-1.0mg/kg.d,bid) and two antibiotics (Amoxicillin30-50mg/kg.d bid, Clarithromycin15-20mg/kg.d bid, Metronidazole15-20mg/kg.d bid ) based on the cytochrome P450 isoenzyme 2C19 genotype and the antimicrobial susceptibility.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard group
Description: All the patients who enrolled in this arm will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) .
Study: NCT01846975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Abatacept
Description: Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
Study: NCT00558103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Oral administration
Study: NCT04082988

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 18F-FDG PET-CT
Description: 18F-FDG PET-CT scan
Study: NCT02112825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Blended supervised-home based walking exercise 3-4 times per week for 30-45 minutes
Study: NCT01719185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine and B12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine
Study: NCT03250468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: Each weekly session will focus on several psychological and behavioural techniques that include sleep restriction, relaxation strategies, cognitive therapy, stimulus control therapy, and education about proper sleep hygiene.
Study: NCT00692770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Sorafenib 400 mg twice daily (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 tablets twice daily (BID)
Study: NCT04248816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Subjects will receive outreach through their providers as is standard of care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-out
Description: Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip for them to get it done at a health system facility.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-out + Incentive
Description: Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip plus an unconditional $20 incentive for them to get it done at a health system facility.
Study: NCT01870765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow oxygen
Description: high-flow oxygen via nasal cannula

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fiberoptic bronchoscopy
Description: fiberoptic bronchoscopy including broncho-alveolar lavage
Study: NCT02769702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar
Description: Acthar 80 IU SC twice a week
Study: NCT00917891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapivirine
Description: dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: dosage form: vaginal gel~frequency: once daily~duration: 6 weeks
Study: NCT01660828

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: remote ischemic preconditioning (RIPC)
Description: RIPC protocol which consist of three 5-min cycles of bilateral forearm ischemia
Study: NCT01076907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm water
Description: Warm water loading of sigmoid colon when spasms occur and waiting for them to subside.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Air will be used instead of warm water for unsedated colonoscopy.
Study: NCT02199405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage of chiropractic and adjusting cervical curvature
Description: Massage of chiropractic and adjusting cervical curvature, 10 minutes, three times one week for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sishi Daoyin
Description: Sishi Daoyin, practicing during 9-11am, once a day for 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional massage
Description: Conventional massage , 15 minutes, three times one week for 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical traction
Study: NCT04492891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 2.5 mg/kg PO BID 7 days

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Treatment
Description: Standard of Care Treatment, N= 25 Patients, 7 days
Study: NCT00175890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Dosing was stratified by age. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for children one month to less than six months old and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for children 6 month to less than 4 years old, was used in this study. The total daily dose was administered b.i.d.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution, which is indistinguishable from the Levetiracetam oral solution.
Study: NCT03325686

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D supplement
Description: D; received 50,000 IU of vitamin D supplement weekly

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01892696

Intervention type: DEVICE
Group type: OTHER
Intervention: varying inspiratory flow waveforms
Description: inspiratory flow waveform was changed, in a randomized sequence using a computer ,to one of the following modalities: 1) constant inspiratory flow; 2) decelerating inspiratory flow Each inspiratory flow waveform was maintained for 30 min. During the last 5 min of this period the physiological signals were collected and measures were performed.
Study: NCT00816101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procellera™ Antimicrobial Dressing
Description: Dressing indicated for partial and full-thickness wounds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex® Border Lite
Description: Self-adherent foam dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adhesive Bandage
Description: Adhesive bandage
Study: NCT03829046

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 weeks of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: 12 weeks of treatment
Study: NCT03674736

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intakes
Description: Four levels of methionine or lysine intakes will be provided by the reference protein drinks, 3 levels of methionine from rice and wheat bread and 3 levels of lysine from chickpeas and lentils
Study: NCT01870765

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fiberoptic bronchoscopy
Description: fiberoptic bronchoscopy including broncho-alveolar lavage
Study: NCT02596074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan (CLS001) topical gel
Study: NCT03674736

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intakes
Description: Four levels of methionine or lysine intakes will be provided by the reference protein drinks, 3 levels of methionine from rice and wheat bread and 3 levels of lysine from chickpeas and lentils

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intakes
Description: Four levels of methionine or lysine intakes will be provided by the reference protein drinks, 3 levels of methionine from rice and wheat bread and 3 levels of lysine from chickpeas and lentils

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intakes
Description: Four levels of methionine or lysine intakes will be provided by the reference protein drinks, 3 levels of methionine from rice and wheat bread and 3 levels of lysine from chickpeas and lentils
Study: NCT03153358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: icotinib 125 milligram three times a day
Study: NCT04165668

Intervention type: OTHER
Intervention: Exposure: First on scene
Description: To be first on scene for resuscitation at the suspected out-of hospital cardiac arrest, before EMS and first responders (fire and police services)
Study: NCT04099784

Intervention type: OTHER
Intervention: Developmental Red flags
Description: Developmental Red flags Questionnaires
Study: NCT02992392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposic
Description: one eye of the participant recieved Lipoic
Study: NCT02596074

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle topical gel
Study: NCT01522066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perineural catheter
Description: Patients in the experimental group will receive a single dose of local anesthetic though an indwelling catheter both before and after surgery.
Study: NCT03153358

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: given radiation for the primary lesion
Study: NCT04348877

Intervention type: OTHER
Group type: OTHER
Intervention: Antibody-Rich Plasma from COVID-19 recovered patients
Description: 400 millimeter of Antibody-Rich Plasma from COVID-19 recovered patients will be transfused to patients with severe or immediately life-threatening COVID-19
Study: NCT03955406

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Low flow Anesthesia
Description: During the initial wash-in period 4 L/min Fresh gas flow will be used.
Study: NCT02992392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tears Naturale Forte
Description: the other eye of the participant recieved Tears Naturale Forte
Study: NCT01447732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-37250/KHK2804
Description: Part 1 is based on the CEP-37250/KHK2804 tolerability and safety data from three subjects enrolled in a cohort, enrollment at the next dose level or additional subjects into the ongoing cohort will occur based upon the number subjects with DLT at a given dose level. Dose depends on subject's body weight. Part 1 includes intervention of CEP-37250/KHK2804.~Part 2 will receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-37250/KHK2804
Description: Part 1 is based on the CEP-37250/KHK2804 tolerability and safety data from three subjects enrolled in a cohort, enrollment at the next dose level or additional subjects into the ongoing cohort will occur based upon the number subjects with DLT at a given dose level. Dose depends on subject's body weight. Part 1 includes intervention of CEP-37250/KHK2804.~Part 2 will receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1.
Study: NCT03955406

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low Flow Anesthesia with fixed fresh gas flow rate
Description: Fresh gas flow rate will be 1 L/min throughout the procedure.
Study: NCT02385539

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The impact of 10 independent variables on the likelihood of not developing hypotension after intrathecal injection.
Description: The study will be conducted to assess the impact of a 10 independent variables (dose and combination of Levobupivacaine with Fentanyl or Sufentanil, age, basal systolic blood pressure (SBP), basal mean arterial pressure (MAP), time to lowest spinal SBP, upper limit of sensory block (dermatoma level), time intervals of sensory recovery for two consecutive dermatoma level (two-segment regression), time intervals of sensory recovery to the twelfth thoracic dermatoma (T12 regression), time intervals of sensory recovery to the first sacral dermatoma (S1 regression) and Body Mass Index) on the likelihood of not developing hypotension after intrathecal injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The impact of 10 independent variables on the likelihood of not developing hypotension after intrathecal injection.
Description: The study will be conducted to assess the impact of a 10 independent variables (dose and combination of Levobupivacaine with Fentanyl or Sufentanil, age, basal systolic blood pressure (SBP), basal mean arterial pressure (MAP), time to lowest spinal SBP, upper limit of sensory block (dermatoma level), time intervals of sensory recovery for two consecutive dermatoma level (two-segment regression), time intervals of sensory recovery to the twelfth thoracic dermatoma (T12 regression), time intervals of sensory recovery to the first sacral dermatoma (S1 regression) and Body Mass Index) on the likelihood of not developing hypotension after intrathecal injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The impact of 10 independent variables on the likelihood of not developing hypotension after intrathecal injection.
Description: The study will be conducted to assess the impact of a 10 independent variables (dose and combination of Levobupivacaine with Fentanyl or Sufentanil, age, basal systolic blood pressure (SBP), basal mean arterial pressure (MAP), time to lowest spinal SBP, upper limit of sensory block (dermatoma level), time intervals of sensory recovery for two consecutive dermatoma level (two-segment regression), time intervals of sensory recovery to the twelfth thoracic dermatoma (T12 regression), time intervals of sensory recovery to the first sacral dermatoma (S1 regression) and Body Mass Index) on the likelihood of not developing hypotension after intrathecal injection.
Study: NCT00113529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib + Sunitinib
Description: Until disease progression or unacceptable toxicity.